Osi Pharmaceuticals — Cell Pathways — Merger or Acquisition (March 2003)
31 slides from Osi Pharmaceuticals's merger presentation, Mar 5, 2003
Slide 1: OSI Pharmaceuticals, March 2003
Click to add Section Header March 2003 NASDAQ / NMS: OSIP
Slide 2: Oncology Franchise Summary
Fully-integrated Oncology Franchise Blockbuster Potential Drug (TarcevaTM) With Compelling Single Agent Activity and a Robust Phase III Approval Plan Under Way Genentech and Roche Alliances Provide Strong Partnerships While Retaining Superior Economics Significant Oncology Pipeline Built Through Int
Slide 3: Defining Our Mission
OSI Pharmaceuticals: Defining Our Mission What Are We Building? A World Class Oncology Franchise: Discovering, Developing and Commercializing High-Quality Oncology Products That Both Extend and Improve the Quality of Life for Cancer Patients Worldwide
Slide 4: Building An Oncology Franchise
Building An Oncology Franchise Strategy Following Return of Rights to TarcevaTM in 2000 Ensure Successful Development, Registration and Commercialization of TarcevaTM Genentech/Roche Alliance Provided Depth to Development and Competitive Commercial Presence Gilead Oncology Acquisition Provided Outst
Slide 5: Cell Pathways Transaction Deal Synopsis
Cell Pathways Transaction Deal Synopsis $33 MM Stock-for-stock Acquisition at $0.85 Per Share Based on OSIP Price at $15 Per Share and Cell Pathways Price at $0.52 Per Share Exchange Ratio: 0.0567 Shares of OSIP Per Share of CLPA $24MM Contingent Value Right (CVR) OSIP Stock at $0.60 Per Share Based
Slide 6: Cell Pathways Asset Overview: Technology Platform
Cell Pathways Transaction Asset Overview: Technology Platform Induction of Apoptosis Through Inhibition of Cgmp-pdes (1, 2, 5, 10) Secondary Platform of Microtubule Disruption MOA of Taxanes and Vincas Strong IP Platform Protecting: Use of Exisulind (Aptosyn) to Treat Cancer Composition of Matter an
Slide 7: Cell Pathways Asset Overview: Clinical Pipeline
Cell Pathways Transaction Asset Overview: Clinical Pipeline CP461 2nd Generation Cgmp-pde Inhibitor Currently in Phase I/II Trials Hints of Activity in Early Clinical Trials Secondary Indication for IBD (With Preliminary Phase II Data) Aptosyn Cgmp-pde Inhibitor Currently in Phase III Trial in Refra
Slide 8: Cell Pathways Asset Overview: Gelclair
Cell Pathways Asset Overview: Gelclair Bio-adherent Oral Gel Containing: Hydrophilic Polymer (Polyvinylpyrrolidone) Hyaluronic Acid (Sodium Hyaluronate) Glycyrrhetinic Acid FDA Approved Medical Device (510K, Dec '01) Management and Relief of Pain Including Oral Mucositis Irritation Due to Oral Surge
Slide 9: 2003 Projected Pipeline / Portfolio Impact
2003 Projected Pipeline / Portfolio Impact Pro-forma - post closing Product Target IND Track Phase I Phase II Phase III Earliest Launch Product Phase I Phase II Phase III Product TARCEVA(tm) (NSCLC,Pancreatic) Gelclair (Oral Mucositis) Aptosyn (NSCLC) OSI-211 (Ovarian, SCLC) OSI-7904L OSI-7836 CP461
Slide 10: Proprietary Targeted Therapies
Proprietary Targeted Therapies
Slide 11: Targeted Therapies: Tarceva, A Potential Cancer Blockbuster
Targeted Therapies: TarcevaTM A Potential Cancer Blockbuster TarcevaTM is an Orally Active, Potent and Selective Inhibitor of HER1(EGFR) Activity A High Proportion of the 1.25 Million New U.S. Cancer Patients Every Year May Benefit from HER1(EGFR) Targeted Drugs TarcevaTM is Being Jointly Developed
Slide 12: Competitive Approaches to Targeting HER1 (EGFR)
Targeted Therapies: TarcevaTM Competitive Approaches to Targeting HER1 (EGFR) TarcevaTM Positioned as an Early Entrant in the Approx.$6 Billion HER1 Market Competitor Agent Expected Launch Date Oral Small Molecule Receptor Tyrosine Kinase Inhibitors Oral Small Molecule Receptor Tyrosine Kinase Inhib
Slide 13: Tarceva: Adjusting to a Changing Landscape
TarcevaTM: Adjusting to a Changing Landscape Do Recent Competitive Developments Represent Opportunity or Threat? Competitors Experienced Delays, Failed Studies and the Emergence of Possible Side Effect Issues in 2002 Are Fundamentals on HER1(EGFR) as a Target Still Strong? Yes: ODAC on Iressa 3rd Li
Slide 14: Tarceva Summary
TarcevaTM Summary OSI and Partners Very Competitively Positioned Only Player Currently With Large, Randomized Placebo-controlled Phase III Studies Assessing HER1(EGFR) Agent as a Monotherapy in Advanced Cancer Size of 2nd/3rd Line NSCLC Study Increased to 700 Patients Accrual Completed Front-Line NS
Slide 15: Tarceva Phase III Program Built on Strong Phase II Data
TarcevaTM Phase III Program Built on Strong Phase II Data Principal Side Effects for All Three Studies Include Rash (Approximately 79%) and Diarrhea (Approximately 45%) TarcevaTM Showed Manageable Side Effects and Anti-tumor Activity As a Single Agent in Phase II Trials in Advanced Patients Who Had
Slide 16: The Opportunity in Refractory NSCLC: Phase II Observations
Tarceva(tm) The Opportunity in Refractory NSCLC: Phase II Observations TarcevaTM Phase II Data Compares Favorably with Published Iressa Data Two CRs in NSCLC Trial TarcevaTM Survival Data Noteworthy The Correlation of Rash and Activity is Compelling All 7 Responders Experienced Rash All 23 Patients
Slide 17: Does Pushing Dose Add Value?
Tarceva(tm) Does Pushing Dose Add Value? AZ: Conservative Phase III Dose Selection Dosing at Approximately 30-65% of Phase I MTD AZ Seem to Have Focused Their Refractory NDA on Quality-of-Life and Palliative Benefits AZ Claim No Difference in Activity Between 250mg/day and 500mg/day OSI: More Aggres
Slide 18: Tarceva Phase II NSCLC Study Survival by Rash
Survival Distribution Function 0.00 0.25 0.50 0.75 1.00 Survival (Days) 0 100 200 300 400 500 600 700 800 Grade #pts Median (95% CI) Days 0 14 46.5 (31 - 66) 1 26 257.0 (146 - 450) 2/3 17 597.0 (327-.) P (0 vs. 1) < 0.0001 P (0 vs. 2/3) < 0.0001 P (1 vs. 2/3) = 0.018 Data Source: ASCO Molecular Ther
Slide 19: Tarceva Phase II and Phase III vs. BSC
TarcevaTM Phase II and Phase III vs. BSC Provide Strong Rationale for Success in 2nd/3rd Line Study vs. BSC TarcevaTM Phase II Results Compared to Best Supportive Care Published Data Suggest Increase of Median Survival by 74% (8.4 vs. 4.6 months) Revised Sample Size in 2nd/3rd Line Study Allows Dete
Slide 20: Tarceva Phase III Program Status
TarcevaTM Phase III Program Status Large, Placebo-controlled, Double-blind Studies Designed to Demonstrate a Survival and Quality-of-Life Benefit for TarcevaTM in Either Combination or Single Agent Settings Non-Small Cell Lung Cancer Program (Primary Indication) Second/Third Line, Single Agent Study
Slide 21: Targeted Therapies CP-547,632 and CP-724,714
Targeted Therapies CP-547,632 (VEGFR Inhibitor (w/Pfizer)) CP-724,714 (HER2-neu (w/Pfizer))
Slide 22: CP-547,632, CP-724,714: Angiogenesis & HER2-neu Inhibition
Targeted Therapies: CP-547,632, CP-724,714 Angiogenesis & HER2-neu Inhibition CP-547,632 Potent & Selective Oral Tyrosine Kinase Inhibitor of VEGFR, an Important Anti-angiogenesis Target Pfizer Completing Phase I Program OSI Receives Royalty on Successful Development CP-724,714 Potent & Selective Or
Slide 23: Next Generation Cytotoxics
Next Generation Cytotoxics - - OSI-211 (Liposomal Lurtotecan) - - OSI-7836 (Gemcitabine Analog) - - OSI-7904L (Liposomal TS Inhibitor)
Slide 24: OSI-211 Liposomal Lurtotecan
OSI-211 Liposomal Lurtotecan A Potent Topoisomerase I Inhibitor Key Marketed Competitor is GSK's Topotecan (Hycamtin(r)) Program Goal Superior Efficacy with Similar or Better Tox Profile vs. Topotecan Improved Scheduling vs. Day 1-5 Schedule Approved for Topotecan Relapsed Ovarian Phase II Data Indi
Slide 25: OSI-7904L Liposomal Thymidylate Synthase Inhibitor
OSI-7904L Liposomal Thymidylate Synthase Inhibitor (TSI) OSI-7904L is a Thymidylate Synthase Inhibitor (TSI), a Well Established Class of Chemotherapeutic Drugs (5FU & XelodaTM ) Most Potent TSI in Development Liposomal Encapsulation is Designed to Reduce Side Effects and Prolong Tumor Exposure to D
Slide 26: OSI-7836 Next Generation Gemcitabine
OSI-7836 Next Generation Gemcitabine Nucleoside Analog with Solid Tumor Activity in Pre-clinical Models Being Developed as an Improved Gemcitabine Gemzar(r) Sales Approximately $660 million in 2001 Unique Mechanism of Action Clearly Demonstrated Anti-tumor Activity in a Variety of Refractory Solid T
Slide 27: Summary: Delivering On An Oncology Franchise
Summary: Delivering On An Oncology Franchise All The Key Attributes For Success in Place Quality People An Outstanding Mix of Discovery, Development & Commercial Expertise Focus on Oncology Functional Skill Sets Strong Integrated Capabilities From Discovery Research Through Development to Commercial
Slide 28: OSI Pharmaceuticals Financial Summary - FY2002
OSI Pharmaceuticals Financial Summary - FY2002 (Dec. 31, 2002) Balance Sheet: (as of December 31, 2002) Cash & Investments $446MM Convertible Debt ($160MM) (due 2009, 4% coupon, $50 conversion) Operating Statement: (as of FY/Sept. 30, 2002) FY2002 Revenues $ 22MM FY2002 Operating costs $131MM (exclu
Slide 29: Key Corporate Goals for 2003
OSI Pharmaceuticals Key Corporate Goals for 2003 Execution on TarcevaTM Manage all Four Phase III Programs Targeted Launch Dates Mid-2004 / 3Q2004 Non-Small Cell Lung Cancer Initiate Programs for Additional Indications and Approaches Corporate Development Close CLPA Deal and Integrate Assets Acquire
Slide 30: Information About the Merger and Where to Find it
Information About the Merger and Where to Find it In connection with the proposed merger, OSI will file with the Securities and Exchange Commission (SEC) a registration statement on Form S-4. The registration statement will include a proxy statement of Cell Pathways for a meeting of its stockholders
Slide 31: OSI Pharmaceuticals, March 2003
Click to add Section Header March 2003 NASDAQ / NMS: OSIP